

# (12) International Application Status Report

**Received at International Bureau:** 25 September 2006 (25.09.2006)

**Information valid as of:** (..)

**Report generated on:** 28 November 2016 (28.11.2016)

**(10) Publication number:**

WO2007/039451

**(43) Publication date:**

12 April 2007 (12.04.2007)

**(26) Publication language:**

English (EN)

**(21) Application Number:**

PCT/EP2006/066507

**(22) Filing Date:**

19 September 2006 (19.09.2006)

**(25) Filing language:**

English (EN)

**(31) Priority number(s):**

05425666.4 (EP)

**(31) Priority date(s):**

23 September 2005 (23.09.2005)

**(31) Priority status:**

Priority document received (in compliance with PCT Rule 17.1)

**(51) International Patent Classification:**

**A61K 39/39** (2006.01); **A61K 39/02** (2006.01); **A61P 37/00** (2006.01)

**(71) Applicant(s):**

DEL PRETE, Gianfranco [IT/IT]; Via Vittorio Emanuele II, 247 I-50134 Firenze (IT) *(for all designated states)*

D'ELIOS, Mario Milco [IT/IT]; Via XX Settembre, 20 I-50053 Empoli (IT) *(for all designated states)*

AMEDEI, Amedeo [IT/IT]; Via Ramazzini, 30 I-50100 Firenze (IT) *(for all designated states)*

CAPPON, Andrea [IT/IT]; Via Molini, 12 I-35010 Padova (IT) *(for all designated states)*

DE BERNARD, Marina [IT/IT]; Via Santa Rosa, 38 I-35141 Padova (IT) *(for all designated states)*

**(72) Inventor(s):**

DEL PRETE, Gianfranco; Via Vittorio Emanuele II, 247 I-50134 Firenze (IT)

D'ELIOS, Mario Milco; Via XX Settembre, 20 I-50053 Empoli (IT)

AMEDEI, Amedeo; Via Ramazzini, 30 I-50100 Firenze (IT)

CAPPON, Andrea; Via Molini, 12 I-35010 Padova (IT)

DE BERNARD, Marina; Via Santa Rosa, 38 I-35141 Padova (IT)

**(74) Agent(s):**

BARDINI, Marco Luigi; Corso Dei Tintori, 25 I-50122 Firenze (IT)

**(54) Title (EN):** USE OF THE NEUTROPHIL ACTIVATING PROTEIN OF HELICOBACTER PYLORI (HP-NAP) AND/OR OF ITS PORTIONS AS ADJUVANTS FOR THE DEVELOPMENT OF T HELPER TYPE 1 (TH1) IMMUNE RESPONSES

**(54) Title (FR):** UTILISATION DE LA PROTEINE D'ACTIVATION DES NEUTROPHILES D'HELICOBACTER PYLORI (HP-NAP) ET/OU DE SES PARTIES COMME ADJUVANTS DANS LE DEVELOPPEMENT DES REPONSES IMMUNES DES LYMPHOCYTES T AUXILIAIRES DE TYPE 1 (TH1)

**(57) Abstract:**

**(EN):** Methods for modifying the quality of the T helper cell immune responses specific for antigens or allergens taking advantage of the Th1-promoting adjuvant effect of the Neutrophil Activating Protein (HP-NAP) of Helicobacter pylori. The adjuvant effect of HP-NAP protein is susceptible of therapeutic use in setting up vaccines or immunopotentiating strategies aimed to elicit Th1-type immune responses and/or to inhibit undesired Th2- or ThO- type immune responses. Clinical applications of the HP-NAP adjuvant effect for Th1 cell responses are: a) inhibition of immunopathogenic or undesired responses of Th0/Th2 type, b) potentiation of weak natural Th1 responses, that per se are unable to exert protection against pathogens or tumors .

**(FR):** L'invention porte sur des méthodes de modification de la qualité des réponses immunes des lymphocytes T auxiliaires spécifiques des antigènes ou des allergènes tirant partie de l'effet adjuvant favorisant Th1 de la protéine activant les neutrophiles (HP-NAP) d'Helicobacter pylori. L'effet adjuvant de la protéine HP-NAP est susceptible d'avoir un rôle thérapeutique dans l'élaboration de vaccins ou de stratégies d'immunopotentialisation afin d'élucider des réponses immunes de type Th1 et/ou d'inhiber les réponses immunes non désirées de type Th2 ou ThO. Les applications cliniques de l'effet adjuvant de HP-NAP des réponses des lymphocytes Th1 sont: a) l'inhibition des réponses immunopathogènes ou non désirées de type Th0/Th2, b) la potentialisation

des réponses naturelles faibles de Th1 qui, en soi, sont incapables d'exercer une protection contre des agents pathogènes ou des tumeurs.

### **International search report:**

Received at International Bureau: 13 March 2007 (13.03.2007) [EP]

### **International Report on Patentability (IPRP) Chapter II of the PCT:**

Not available

### **(81) Designated States:**

AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

European Patent Office (EPO) : AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, MD, RU, TJ, TM